Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor ActivityRobert M. Campbell, Xiang S. Ye, Bryan D. Anderson et al.|Molecular Cancer Therapeutics|2013Cited by 121
Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine modelsHarold B. Brooks, F. George Njoroge|Scientific Reports|2018Cited by 21
Data from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor ActivityRobert M. Campbell, Xiang S. Ye, Bryan D. Anderson et al.|Unknown|2023Cited by 0
Supplementary Methods, Table 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor ActivityRobert M. Campbell, Xiang S. Ye, Bryan D. Anderson et al.|Unknown|2023Cited by 0
Supplementary Figure 2 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor ActivityRobert M. Campbell, Xiang S. Ye, Bryan D. Anderson et al.|Unknown|2023Cited by 0